Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 1
2011 1
2013 1
2014 1
2015 1
2017 1
2018 3
2020 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Verotoxin Receptor-Based Pathology and Therapies.
Lingwood C. Lingwood C. Front Cell Infect Microbiol. 2020 Mar 31;10:123. doi: 10.3389/fcimb.2020.00123. eCollection 2020. Front Cell Infect Microbiol. 2020. PMID: 32296648 Free PMC article. Review.
Verotoxin, VT (aka Shiga toxin,Stx) is produced by enterohemorrhagic E. coli (EHEC) and is the key pathogenic factor in EHEC-induced hemolytic uremic syndrome (eHUS-hemolytic anemia/thrombocytopenia/glomerular infarct) which can follow gastrointestinal …
Verotoxin, VT (aka Shiga toxin,Stx) is produced by enterohemorrhagic E. coli (EHEC) and is the key pathogenic factor in EHEC-induced hemo …
The susceptibility of the kidney to alternative pathway activation-A hypothesis.
Thurman JM, Harrison RA. Thurman JM, et al. Immunol Rev. 2023 Jan;313(1):327-338. doi: 10.1111/imr.13168. Epub 2022 Nov 12. Immunol Rev. 2023. PMID: 36369971 Review.
In particular, AP activation is the key driver of two severe kidney diseases: atypical hemolytic uremic syndrome and C3 glomerulopathy. Both conditions are associated with a variety of predisposing molecular defects in AP regulation, such as genetic va …
In particular, AP activation is the key driver of two severe kidney diseases: atypical hemolytic uremic syndrome …
Diseases of complement dysregulation-an overview.
Wong EKS, Kavanagh D. Wong EKS, et al. Semin Immunopathol. 2018 Jan;40(1):49-64. doi: 10.1007/s00281-017-0663-8. Epub 2018 Jan 11. Semin Immunopathol. 2018. PMID: 29327071 Free PMC article. Review.
Atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy (C3G), and paroxysmal nocturnal hemoglobinuria (PNH) are prototypical disorders of complement dysregulation. ...The mechanism underlying the dysregulation also varies with predominant acquire …
Atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy (C3G), and paroxysmal nocturnal hemoglobinuria (PNH …
Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria.
Merrill SA, Brodsky RA. Merrill SA, et al. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):371-376. doi: 10.1182/asheducation-2018.1.371. Hematology Am Soc Hematol Educ Program. 2018. PMID: 30504334 Free PMC article. Review.
Atypical hemolytic uremic syndrome (aHUS); hemolysis, elevated liver function tests, and low platelets syndrome; and transplant-associated thrombotic microangiopathy are related conditions, in that many patients harbor germline heterozygous muta …
Atypical hemolytic uremic syndrome (aHUS); hemolysis, elevated liver function tests, and low platelets syndro …
Advances in our understanding of the pathogenesis of hemolytic uremic syndromes.
Bowen EE, Coward RJ. Bowen EE, et al. Am J Physiol Renal Physiol. 2018 Mar 1;314(3):F454-F461. doi: 10.1152/ajprenal.00376.2017. Epub 2017 Nov 22. Am J Physiol Renal Physiol. 2018. PMID: 29167171 Free PMC article. Review.
Hemolytic uremic syndrome (HUS) is major global health care issue as it is the leading cause of acute kidney injury in children. It is a triad of acute kidney injury, microangiopathic hemolytic anemia, and thrombocytopenia. In recent years, major advan …
Hemolytic uremic syndrome (HUS) is major global health care issue as it is the leading cause of acute kidney injury in …
New insights into postrenal transplant hemolytic uremic syndrome.
Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Frémeaux-Bacchi V, Legendre C. Zuber J, et al. Nat Rev Nephrol. 2011 Jan;7(1):23-35. doi: 10.1038/nrneph.2010.155. Epub 2010 Nov 23. Nat Rev Nephrol. 2011. PMID: 21102542 Review.
After renal transplantation, hemolytic uremic syndrome (HUS) may occur either as a recurrent or de novo form. ...This finding suggests that the burden of endothelial injury in a post-transplantation setting may trigger de novo HUS in the presence of mild gene …
After renal transplantation, hemolytic uremic syndrome (HUS) may occur either as a recurrent or de novo form. ...This f …
Atypical aHUS: State of the art.
Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, Kavanagh D, Noris M, Pickering M, Sanchez-Corral P, Skerka C, Zipfel P, Smith RJ. Nester CM, et al. Mol Immunol. 2015 Sep;67(1):31-42. doi: 10.1016/j.molimm.2015.03.246. Epub 2015 Apr 3. Mol Immunol. 2015. PMID: 25843230 Review.
Tremendous advances in our understanding of the thrombotic microangiopathies (TMAs) have revealed distinct disease mechanisms within this heterogeneous group of diseases. As a direct result of this knowledge, both children and adults with complement-mediated TMA now enjoy …
Tremendous advances in our understanding of the thrombotic microangiopathies (TMAs) have revealed distinct disease mechanisms within …
Complement activation in diseases presenting with thrombotic microangiopathy.
Meri S. Meri S. Eur J Intern Med. 2013 Sep;24(6):496-502. doi: 10.1016/j.ejim.2013.05.009. Epub 2013 Jun 4. Eur J Intern Med. 2013. PMID: 23743117 Review.
The complement system contains a great deal of biological "energy". This is demonstrated by the atypical hemolytic uremic syndrome (aHUS), which is a thrombotic microangiopathy (TMA) characterized by endothelial and blood cell damage and thrombotic vas …
The complement system contains a great deal of biological "energy". This is demonstrated by the atypical hemolytic uremic …
Pathogenesis and prognosis of thrombotic microangiopathy.
Nangaku M, Nishi H, Fujita T. Nangaku M, et al. Clin Exp Nephrol. 2007 Jun;11(2):107-114. doi: 10.1007/s10157-007-0466-7. Epub 2007 Jun 28. Clin Exp Nephrol. 2007. PMID: 17593509 Review.
Included in the broad category of TMA are the hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP). ...Although most patients with typical HUS recover renal functions, recent analysis has shown that typical HUS is not a benign dise …
Included in the broad category of TMA are the hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura ( …
Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach.
Grumach AS, Kirschfink M. Grumach AS, et al. Mol Immunol. 2014 Oct;61(2):110-7. doi: 10.1016/j.molimm.2014.06.030. Epub 2014 Jul 15. Mol Immunol. 2014. PMID: 25037634 Review.
Complement deficiencies comprise between 1 and 10% of all primary immunodeficiencies (PIDs) according to national and supranational registries. ...Mutations affecting the regulators factor H, factor I, or CD46 and of C3 and factor B leading to severe dysregulation of the a …
Complement deficiencies comprise between 1 and 10% of all primary immunodeficiencies (PIDs) according to national and supranational r …